Columvi (glofitamab-gxbm)

General Description

Columvi (glofitamab-gxbm) is a bispecific antibody that targets CD20 on B-cells and engages CD3 on T-cells. It is prescribed for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).¹ The U.S. FDA approved Columvi in June 2023.²

Getting Columvi (glofitamab-gxbm) in India

Columvi (glofitamab-gxbm)is approved in the U.S., Europe, and other countries, but it is not yet commercially available in India. However, eligible patients in India may access this important therapy through the Named Patient Program (NPP).

MitoGENE helps patients obtain Columvi (glofitamab-gxbm) legally and safely, in collaboration with their treating doctor. We assist with documentation, import coordination, and delivery—ensuring full compliance with Indian regulatory guidelines.

If you or a loved one needs Columvi (glofitamab-gxbm), MitoGENE is here to guide you through every step of the process.

---

Disease Indications:Lymphoma

Manufacturer:Genentech, Inc

Usage:Intravenous

Medicine Approved by:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)

---

Available Dosage Form & Package:

• single-dose vial x 2.5 mg/2.5 mL
• single-dose vial x 10 mg/10 mL

---

Shipping:Cold Chain Shipping. Certain medicines can be affected by heat, light, or improper handling. Cold chain shipping uses temperature-controlled packaging and transport provided by specialized medical couriers to keep these medicines stable and effective. Due to the added care and equipment involved, this method is often more expensive than standard shipping.